Minute Insight: Strados Earns FDA 510(k) To Let Patients Use RESP Sensor At Home
Executive Summary
The FDA cleared Strados’ RESP sensor to be incorporated into at-home remote monitoring of patients with pulmonary disease in addition to in-hospital monitoring. Strados expects the in-home indication will help physicians better understand their patients’ respiratory health “journey.”
You may also be interested in...
Minute Insight: Biotronik Launches Remote Monitor That Can Prevent Heart Failure Hospitalizations
The HeartInsight algorithm combines heart failure parameters into a predictive score and alerts physicians if a patient with an implanted ICD or CRT-D is at higher risk of hospitalization. Biotronik will roll out HeartInsight in Europe in April.
Remote Monitoring A Potential Strategy To Recruit Older Adults Into Oncology Trials
Final FDA guidance also suggests sponsors recruit representative populations and limit exclusions.
Studies On Treating COVID-19 Inflammation And Migraines Also Weigh Efficacy Of Remote Trials
Preliminary data from Cold Springs Harbor Laboratory study suggest famotidine could mitigate inflammatory symptoms of COVID-19 in adults. Research sponsored by Nestle Health Science in Canada also points to remote studies likely to continue after emerging as a pandemic innovation.